Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AcelRx slumps as FDA demands another Zalviso trial

This article was originally published in Scrip

Executive Summary

AcelRx Pharmaceuticals saw its share price slump on news that the US FDA now wants an additional clinical trial conducted "to assess the risk of inadvertent dispensing and overall risk of dispensing failures" of Zalviso, said the Redwood City, CA-based firm. Zalviso is a pre-programmed, non-invasive, handheld system, which delivers 15mcg per dose as needed of sufentanil, an opioid, allowing hospital patients to self-dose in managing their pain. Last July, in a surprise move, the FDA rejected Zalviso's NDA. However, the complete response letter did not mention the need for additional clinical data. AcelRx now plans to meet with the FDA to clarify the situation and discuss the potential design and objectives of new study. An NDA resubmission for Zalviso will not happen this quarter, as previously planned. AcelRx will provide an update on the timing of the resubmission of the Zalviso NDA after meeting with the FDA, it said.

You may also be interested in...



Pain In The (ER) Battlefield: AcelRx Reports Positive ARX-04 Results

AcelRx reports fast-acting, pain-reducing data for ARX-04 in emergency room-treated trauma patients, which is the setting that most closely resembles battlefield situations experienced by personnel in the US military – the Phase III program's co-funder.

UK Reimbursement Decisions Focus Mostly On Cancer

The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.

Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts

While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.

Topics

Related Companies

UsernamePublicRestriction

Register

SC100339

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel